These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 25470867)

  • 21. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology.
    Loria P; Marchesini G; Nascimbeni F; Ballestri S; Maurantonio M; Carubbi F; Ratziu V; Lonardo A
    Atherosclerosis; 2014 Jan; 232(1):99-109. PubMed ID: 24401223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis.
    Contos MJ; Cales W; Sterling RK; Luketic VA; Shiffman ML; Mills AS; Fisher RA; Ham J; Sanyal AJ
    Liver Transpl; 2001 Apr; 7(4):363-73. PubMed ID: 11303298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of development of hepatocellular carcinoma in patients with NASH-related cirrhosis.
    Amarapurkar DN; Dharod M; Gautam S; Patel N
    Trop Gastroenterol; 2013; 34(3):159-63. PubMed ID: 24851525
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease.
    Bhagat V; Mindikoglu AL; Nudo CG; Schiff ER; Tzakis A; Regev A
    Liver Transpl; 2009 Dec; 15(12):1814-20. PubMed ID: 19938128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NASH and HCC.
    Page JM; Harrison SA
    Clin Liver Dis; 2009 Nov; 13(4):631-47. PubMed ID: 19818310
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes of liver transplantation for cryptogenic cirrhosis: a single-center study of 71 patients.
    Sanjeevi A; Lyden E; Sunderman B; Weseman R; Ashwathnarayan R; Mukherjee S
    Transplant Proc; 2003 Dec; 35(8):2977-80. PubMed ID: 14697954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic liver disease in diabetes mellitus.
    Amarapurkar D; Das HS
    Trop Gastroenterol; 2002; 23(1):3-5. PubMed ID: 12170918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fatty liver.
    Thaler H
    Tokai J Exp Clin Med; 1980 Apr; 5(2):233-42. PubMed ID: 7414634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C.
    Younossi ZM; McCullough AJ; Ong JP; Barnes DS; Post A; Tavill A; Bringman D; Martin LM; Assmann J; Gramlich T; Mullen KD; O'Shea R; Carey WD; Ferguson R
    J Clin Gastroenterol; 2004 Sep; 38(8):705-9. PubMed ID: 15319656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Alcoholic liver cirrhosis].
    Khazanov AI; Ivlev AS; Sementsov PN
    Klin Med (Mosk); 1988 Feb; 66(2):129-33. PubMed ID: 3374037
    [No Abstract]   [Full Text] [Related]  

  • 31. Explant liver evaluation decodes the mystery of cryptogenic cirrhosis!
    Jain M; Venkataraman J; Varghese J; Vij M; Reddy MS; Rela M
    JGH Open; 2020 Feb; 4(1):39-43. PubMed ID: 32055695
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Nonalcoholic steatohepatitis: a brief review on its concept].
    Ishii H
    Nihon Rinsho; 2006 Jun; 64(6):1021-4. PubMed ID: 16768104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics and diagnosis of NAFLD/NASH.
    Hashimoto E; Taniai M; Tokushige K
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():64-70. PubMed ID: 24251707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cryptogenic cirrhosis: what are we missing?
    Caldwell S
    Curr Gastroenterol Rep; 2010 Feb; 12(1):40-8. PubMed ID: 20425483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis.
    Ratziu V; Bonyhay L; Di Martino V; Charlotte F; Cavallaro L; Sayegh-Tainturier MH; Giral P; Grimaldi A; Opolon P; Poynard T
    Hepatology; 2002 Jun; 35(6):1485-93. PubMed ID: 12029634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The significance of the hepatitis B virus in the development of chronic liver diseases].
    Khazanov AI; Ivlev AS; Rumiantsev ON; Gerasimov GM
    Voen Med Zh; 1988 Nov; (11):59-60. PubMed ID: 3227683
    [No Abstract]   [Full Text] [Related]  

  • 37. Prevalence of metabolic syndrome, obesity and diabetes type 2 in cryptogenic cirrhosis.
    Tellez-Avila FI; Sanchez-Avila F; García-Saenz-de-Sicilia M; Chavez-Tapia NC; Franco-Guzman AM; Lopez-Arce G; Cerda-Contreras E; Uribe M
    World J Gastroenterol; 2008 Aug; 14(30):4771-5. PubMed ID: 18720537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of obesity, diabetes mellitus and hyperlipidaemia in patients with cryptogenic liver cirrhosis.
    Duseja A; Nanda M; Das A; Das R; Bhansali A; Chawla Y
    Trop Gastroenterol; 2004; 25(1):15-7. PubMed ID: 15303464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical characteristics of patients with cryptogenic liver cirrhosis in Okinawa, Japan.
    Sakugawa H; Nakasone H; Nakayoshi T; Kawakami Y; Yamashiro T; Maeshiro T; Kobashigawa K; Kinjo F; Saito A
    Hepatogastroenterology; 2003; 50(54):2005-8. PubMed ID: 14696453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recurrence of non-alcoholic steatohepatitis and cryptogenic cirrhosis following orthotopic liver transplantation in the context of the metabolic syndrome.
    El Atrache MM; Abouljoud MS; Divine G; Yoshida A; Kim DY; Kazimi MM; Moonka D; Huang MA; Brown K
    Clin Transplant; 2012; 26(5):E505-12. PubMed ID: 23061759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.